Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
146.35
+0.74 (+0.51%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product
Via
Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
January 09, 2024
Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.
Via
InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
January 09, 2024
Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.
Via
InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
Last year wasn't great for either stock, but that's no reason to ignore them.
Via
The Motley Fool
The Latest Analyst Ratings for Sarepta Therapeutics
December 12, 2023
Via
Benzinga
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
December 09, 2023
Can this struggling stock turn its fortunes around?
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 21, 2023
Via
Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Via
Benzinga
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
3 Things About Sarepta Therapeutics Every Smart Investor Knows
December 28, 2023
Mastering this stock requires appreciating a few scientific nuances.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
Via
Benzinga
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
The biotech has what it takes to overcome recent obstacles.
Via
The Motley Fool
Analyst Ratings for Sarepta Therapeutics
November 02, 2023
Via
Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
December 22, 2023
Both develop medicines for rare diseases, and each aims to conquer a niche market.
Via
The Motley Fool
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
December 17, 2023
Many investors are bailing out, but that might be a mistake.
Via
The Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
December 08, 2023
These strong stocks are still available at a great price. That may not be the case a whole lot longer.
Via
The Motley Fool
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.
Via
InvestorPlace
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the
Via
Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said HubSpot, Inc. (NYSE: HUBS) is like a "mini-Salesforce, it’s got incredible growth, and people like growth again.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Sarepta Therapeutics Stock a Bad-News Buy?
November 09, 2023
Analysts still expect some sizable returns from the stock.
Via
The Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
Just because a stock is "on sale" doesn't inherently make it worth purchasing.
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
November 02, 2023
SRPT earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
What's Going On With Biotech Contract Service Firm Catalent Stock Today?
October 31, 2023
Catalent Inc (NYSE: CTLT) shares are trading lower due to its significant exposure to Sarepta Therapeutics Inc (NASDAQ: SRPT) on the back of disappointing data from a pivotal gene therapy trial.
Via
Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
October 31, 2023
Sarepta Therapeutics Inc's (NASDAQ: SRPT) EMBARK Phase 3 study of Elevidys in ambulatory boys (those who can walk) with Duchenne muscular dystrophy aged 4-7 years failed to
Via
Benzinga
Earnings Scheduled For November 1, 2023
November 01, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.